Systemic lupus erythematosus (SLE) is a disease that affects women in their reproductive years. With the development of medical treatment, SLE is no longer a contraindication to pregnancy. Generally speaking, only 7% of SLE patients with no significant organ damage, stable disease for one year or more, discontinuing cytotoxic immunosuppressants (cyclophosphamide, methotrexate, etc.) for more than six months and requiring only low-dose hormone therapy can become pregnant, and most of them can safely become pregnant and have children, but regular specialist follow-up and medication adjustment are required. Adrenocorticosteroids are the mainstay of treatment for SLE and are the most important treatment to reduce the rate of pregnancy loss and control disease activity. Dexamethasone and betamethasone should not be used in pregnancy. Prednisone, methylprednisolone or succinyl hydrocortisone can be used. Since 11-β-dehydrogenase produced by the placenta can oxidize prednisone to the inactive 11-ketone base, the drug has the least effect on the fetus, so prednisone is preferred for oral hormones in pregnancy. The dose of prednisone should preferably be ≤7.5 mg/d and closely monitored throughout pregnancy, and the dose of prednisone should be adjusted according to the condition.